Fig. 8From: Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisEffect of roflumilast vs. placebo on SGRQ. CI, confidence interval; SD, standard derivation; SGRQ, St George’s Respiratory QuestionnaireBack to article page